| 1566 CME examination KA Williams, AH Huang, M Belzberg, SG Kwatra, DM Elston, ... | | 2020 |
| 69-Year-Old Man With Dysuria and Right Lower Abdominal Pain J Wieland, BK Chang, W Ding Mayo Clinic Proceedings 97 (6), 1182-1187, 2022 | | 2022 |
| A conserved calcineurin-binding motif in human T lymphotropic virus type 1 p121 functions to modulate NFAT activation. S Kim, W Ding, B Albrecht, PL Green, MD Lairmore AIDS RESEARCH AND HUMAN RETROVIRUSES 19, S26-S27, 2003 | | 2003 |
| A conserved calcineurin-binding motif in human T lymphotropic virus type 1 p12I functions to modulate nuclear factor of activated T cell activation S Kim, W Ding, B Albrecht, PL Green, MD Lairmore Journal of Biological Chemistry 278 (18), 15550-15557, 2003 | 89 | 2003 |
| A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia PJ Hampel, M Swaminathan, KA Rogers, EM Parry, JA Burger, MS Davids, ... Blood Advances 8 (10), 2342-2350, 2024 | 1 | 2024 |
| A novel mechanism of innate immune dysfunction in untreated Chronic Lymphocytic Leukemia. BA Manso, H Zhang, MG Mikkelson, KA Gwin, CR Secreto, W Ding, ... The Journal of Immunology 200 (1_Supplement), 178.18-178.18, 2018 | | 2018 |
| A once daily, oral, triple combination of BTK inhibitor, mTOR inhibitor and IMiD for treatment of relapsed/refractory Richter's transformation and de novo diffuse large B-cell … AR Mato, SJ Schuster, FM Foss, I Isufi, SK Kothari, W Ding, DM Brander, ... Blood 136, 21-22, 2020 | 14 | 2020 |
| A phase Ia/Ib study exploring the synthetic lethality of the orally administered novel BTK inhibitor, dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide in … AR Mato, SJ Schuster, FM Foss, I Isufi, W Ding, DM Brander, A Sitlinger, ... Blood 134, 810, 2019 | 10 | 2019 |
| A randomized phase 2 study comparing acalabrutinib with or without obinutuzumab in the treatment of early stage high risk patients with Chronic Lymphocytic Leukemia (CLL) or … SA Parikh, E Muchtar, B Laplant, W Ding, S Ailawadhi, A Koehler, TG Call, ... Blood 134, 4306, 2019 | 3 | 2019 |
| A Role for TNF-α in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction BA Manso, J Krull, K Gwin, P Lothert, CR Secreto, W Ding, SA Parikh, ... Blood 134, 4276, 2019 | | 2019 |
| A study of frontline therapy in adults> 80 years with chronic lymphocytic leukemia (CLL). M Tsang, PJ Hampel, KG Rabe, W Ding, JF Leis, S Kenderian, Y Wang, ... Journal of Clinical Oncology 41 (16_suppl), 12057-12057, 2023 | | 2023 |
| A041702: a randomized phase III study of ibrutinib plus obinutuzumab versus ibrutinib plus venetoclax and obinutuzumab in untreated older patients (≥ 70 years of age) with … JA Woyach, AS Ruppert, G Perez, AM Booth, D Feldman, EG Dib, A Jatoi, ... Blood 138, 3728, 2021 | 3 | 2021 |
| Aberrant expression of lymphoid enhancer–binding factor 1 in Hodgkin lymphoma A Ravindran, PJ Kurtin, RL King, J Yuan, AL Feldman, KL Rech, ... Human Pathology 125, 2-10, 2022 | 5 | 2022 |
| Abstract B02: The Akt inhibitor MK-2206 in combination with rituximab and bendamustine demonstrates efficacy in relapsed/refractory chronic lymphocytic leukemia: Updated … JT Larsen, TD Shanafelt, JF Leis, BR LaPlant, TG Call, CS Zent, ... Molecular Cancer Therapeutics 14 (7_Supplement), B02-B02, 2015 | | 2015 |
| Activation of nuclear factor of activated T cells (NFAT) by human T-lymphotropic virus type 1 accessory protein p12 (I) B Albrecht, CD D'Souza, W Ding, SJ Kim, S Tridandapani, KM Coggeshall, ... AIDS RESEARCH AND HUMAN RETROVIRUSES 17, S21-S21, 2001 | | 2001 |
| Activation of Nuclear Factor of Activated T Cells by Human T-Lymphotropic Virus Type 1 Accessory Protein p12I B Albrecht, CD D'Souza, W Ding, S Tridandapani, KM Coggeshall, ... Journal of virology 76 (7), 3493-3501, 2002 | 113 | 2002 |
| Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare PJ Hampel, TG Call, W Ding, E Muchtar, SS Kenderian, Y Wang, JF Leis, ... American journal of hematology 95 (3), E57-E60, 2020 | 8 | 2020 |
| Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202 AS Ruppert, AM Booth, W Ding, NL Bartlett, DM Brander, S Coutre, ... Leukemia 35 (10), 2854-2861, 2021 | 18 | 2021 |
| Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: results from the N1087 alliance study JT Larsen, TD Shanafelt, JF Leis, B LaPlant, T Call, A Pettinger, C Hanson, ... American journal of hematology 92 (8), 759-763, 2017 | 26 | 2017 |
| Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis W Ding, TD Shanafelt, CE Lesnick, C Erlichman, JF Leis, C Secreto, ... British journal of haematology 164 (1), 146, 2014 | 28 | 2014 |
